Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study
暂无分享,去创建一个
R. Murray | A. Egerton | S. Lawrie | O. Howes | E. Kravariti | T. Collier | J. Walters | J. MacCabe | J. Lees | R. Drake | S. Lewis | B. Deakin | J. Donocik | A. Murphy | L. Kassoumeri | Charlotte Stockton-Powdrell | Edward Millgate | R. Murray | J. Walters | Jacek G. Donocik
[1] A. Egerton,et al. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis , 2021, Psychological Medicine.
[2] W. Honer,et al. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. , 2020, Schizophrenia bulletin.
[3] R. Emsley,et al. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA) , 2020, Schizophrenia bulletin.
[4] E. Rostrup,et al. Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis , 2020, Biological Psychiatry.
[5] S. Dienel,et al. Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development , 2020, Biomarkers in neuropsychiatry.
[6] A. Tanskanen,et al. The clinical course of schizophrenia in women and men—a nation-wide cohort study , 2020, npj Schizophrenia.
[7] E. Rostrup,et al. Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years , 2020, Psychological Medicine.
[8] C. Li,et al. Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★ , 2020, Psychiatry Research: Neuroimaging.
[9] K. Ryzhikova,et al. Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms , 2019, Neurology, Psychiatry and Brain Research.
[10] R. Murray,et al. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies , 2019, Psychological Medicine.
[11] Peter B. Jones,et al. Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. , 2019, The American journal of psychiatry.
[12] G. Kirov,et al. Clinical indicators of treatment-resistant psychosis , 2019, The British Journal of Psychiatry.
[13] S. Potkin,et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. , 2019, The Journal of clinical psychiatry.
[14] P. Bozzatello,et al. Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review , 2019, Front. Psychiatry.
[15] R. Burns,et al. A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis , 2019, Substance use & misuse.
[16] Egill Rostrup,et al. Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients , 2018, Psychological Medicine.
[17] M. Fornaro,et al. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses , 2018, Psychiatry Research.
[18] Peter B. Jones,et al. Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study , 2018, Psychological Medicine.
[19] E. Bora,et al. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia , 2017, Psychological Medicine.
[20] M. Medina-Mora,et al. Validity of the posttraumatic stress disorders (PTSD) checklist in pregnant women , 2017, BMC Psychiatry.
[21] R. Murray,et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors , 2017, Psychological Medicine.
[22] C. Gasse,et al. Predictors of Nonhospitalization and Functional Response in Clozapine Treatment: A Nationwide, Population-Based Cohort Study , 2017, Journal of clinical psychopharmacology.
[23] L. K. Hansen,et al. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology , 2017, Translational Psychiatry.
[24] Ryuhei So,et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study , 2017, Psychiatry Research.
[25] A. Egerton,et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review , 2017, BMC Psychiatry.
[26] F. Gaughran,et al. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics , 2016, Pharmacogenomics and personalized medicine.
[27] R. Murray,et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses , 2016, Psychological Medicine.
[28] C. Correll,et al. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study , 2016, CNS Drugs.
[29] C. Gasse,et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. , 2016, The lancet. Psychiatry.
[30] B. Misiak,et al. Profiling cognitive impairment in treatment-resistant schizophrenia patients , 2016, Psychiatry Research.
[31] J. MacCabe,et al. Service users’ and carers’ views on research towards stratified medicine in psychiatry: a qualitative study , 2015, BMC Research Notes.
[32] V. Mohan. Faeco-prevalence of Campylobacter jejuni in urban wild birds and pets in New Zealand , 2015, BMC Research Notes.
[33] L. Farde,et al. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia , 2014, Schizophrenia Research.
[34] Philip D. Harvey. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? , 2014, The Journal of clinical psychiatry.
[35] F. Iasevoli,et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses , 2013, Psychiatry Research.
[36] E. Stip,et al. Clozapine and visuospatial processing in treatment-resistant schizophrenia , 2013, Cognitive neuropsychiatry.
[37] J. O. Johannessen,et al. Ten year neurocognitive trajectories in first-episode psychosis , 2013, Front. Hum. Neurosci..
[38] T. Kosten,et al. Gender differences in cognitive function of patients with chronic schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[39] A. Lobo,et al. Negative Symptoms and Executive Function in Schizophrenia: Does Their Relationship Change with Illness Duration? , 2012, Psychopathology.
[40] Jayashri Kulkarni,et al. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review , 2012, Schizophrenia research and treatment.
[41] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[42] Aysenil Belger,et al. Attention deficits in schizophrenia — Preliminary evidence of dissociable transient and sustained deficits , 2010, Schizophrenia Research.
[43] J. Peña,et al. Verbal Fluency in Schizophrenia: Does Cognitive Performance Reflect the Same Underlying Mechanisms in Patients and Healthy Controls? , 2010, The Journal of nervous and mental disease.
[44] Peter B. Jones,et al. Neuropsychological functioning in first-episode schizophrenia , 2009, British Journal of Psychiatry.
[45] S. Faraone,et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. , 2009, Neuropsychology.
[46] A M McIntosh,et al. Working memory in schizophrenia: a meta-analysis , 2008, Psychological Medicine.
[47] Philip D. Harvey,et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) , 2008, Schizophrenia Research.
[48] A. Minassian,et al. Stability of attention deficits in schizophrenia , 2007, Schizophrenia Research.
[49] F. Craik,et al. Cognition through the lifespan: mechanisms of change , 2006, Trends in Cognitive Sciences.
[50] E. Kandel,et al. Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.
[51] Junghee Lee,et al. Working memory impairments in schizophrenia: a meta-analysis. , 2005, Journal of abnormal psychology.
[52] Cameron S Carter,et al. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. , 2005, Schizophrenia bulletin.
[53] Philip McGuire,et al. Association of symptoms and executive function in schizophrenia and bipolar disorder , 2005, Schizophrenia Research.
[54] J. Sweeney,et al. Impairment of verbal memory and learning in antipsychotic-naı̈ve patients with first-episode schizophrenia , 2004, Schizophrenia Research.
[55] B. Wexler,et al. Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits , 2004, Schizophrenia Research.
[56] Philip D. Harvey,et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.
[57] R. Murray,et al. Verbal memory deficit in patients with schizophrenia: an important future target for treatment , 2004, Expert review of neurotherapeutics.
[58] T. Goldberg,et al. Letter and category fluency in schizophrenic patients: a meta-analysis , 2003, Schizophrenia Research.
[59] C. Benkelfat,et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers , 2002, Schizophrenia Research.
[60] A. Arnsten. Catecholamine modulation of prefrontal cortical cognitive function , 1998, Trends in Cognitive Sciences.
[61] V. Peralta,et al. Illness duration and neuropsychological impairments in schizophrenia. , 1998, Schizophrenia research.
[62] G. Kirov,et al. Randomised controlled trial of compliance therapy , 1998, British Journal of Psychiatry.
[63] N. Andreasen,et al. Soft signs and neuropsychological performance in schizophrenia. , 1996, The American journal of psychiatry.
[64] P. Hayward,et al. Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.
[65] Klaus P. Ebmeier,et al. Magnetic Resonance Imaging and Single Photon Emission Tomography in Treatment-Responsive and Treatment-Resistant Schizophrenia , 1995, British Journal of Psychiatry.
[66] J. Teresi,et al. Gender differences in cognition in schizophrenia , 1992, Schizophrenia Research.
[67] G. Arbanas. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .
[68] H. Elkis. Treatment-resistant schizophrenia. , 2007, The Psychiatric clinics of North America.
[69] E. Miller,et al. An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.
[70] R. C. Smith,et al. Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. , 1999, Schizophrenia bulletin.
[71] D. Velligan,et al. Executive function in schizophrenia. , 1999, Seminars in clinical neuropsychiatry.
[72] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[73] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.